Equities analysts expect that Intec Pharma Ltd (NASDAQ:NTEC) will announce ($0.19) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which suggests a positive year over year growth rate of 40.6%. The firm is scheduled to issue its next earnings results on Friday, April 6th.
According to Zacks, analysts expect that Intec Pharma will report full year earnings of ($1.35) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will post earnings of ($0.89) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Intec Pharma.
A number of research firms have commented on NTEC. Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research report on Saturday. CIBC reaffirmed an “outperform” rating and issued a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Oppenheimer set a $15.00 target price on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. ValuEngine cut Intec Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Maxim Group set a $8.00 price target on Intec Pharma and gave the stock a “buy” rating in a report on Friday, November 17th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $11.15.
Intec Pharma (NTEC) opened at $6.80 on Wednesday. Intec Pharma has a 52 week low of $4.20 and a 52 week high of $9.80.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.